Partners Capital Investment Group LLP Has $311,000 Position in Stryker Co. (NYSE:SYK)

Partners Capital Investment Group LLP decreased its position in Stryker Co. (NYSE:SYKFree Report) by 10.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,037 shares of the medical technology company’s stock after selling 121 shares during the quarter. Partners Capital Investment Group LLP’s holdings in Stryker were worth $311,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of SYK. Burkett Financial Services LLC bought a new stake in Stryker during the fourth quarter valued at about $25,000. Farmers & Merchants Trust Co of Chambersburg PA increased its position in Stryker by 203.3% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 91 shares of the medical technology company’s stock worth $27,000 after buying an additional 61 shares during the period. Rogco LP acquired a new position in Stryker during the 4th quarter valued at $30,000. DSM Capital Partners LLC acquired a new position in shares of Stryker during the fourth quarter valued at about $34,000. Finally, HBC Financial Services PLLC bought a new stake in shares of Stryker in the fourth quarter valued at about $37,000. 77.09% of the stock is owned by institutional investors.

Stryker Trading Up 0.2 %

Shares of SYK stock traded up $0.57 on Friday, reaching $341.09. The company had a trading volume of 2,175,319 shares, compared to its average volume of 1,348,204. The company has a 50-day moving average of $338.39 and a 200-day moving average of $326.66. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The stock has a market cap of $129.94 billion, a PE ratio of 38.94, a PEG ratio of 2.69 and a beta of 0.91. The company has a current ratio of 1.71, a quick ratio of 0.99 and a debt-to-equity ratio of 0.56.

Stryker (NYSE:SYKGet Free Report) last issued its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.36 by $0.14. Stryker had a net margin of 16.03% and a return on equity of 23.05%. The firm had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. During the same quarter in the prior year, the firm earned $2.14 earnings per share. The business’s quarterly revenue was up 9.7% on a year-over-year basis. On average, equities analysts forecast that Stryker Co. will post 11.95 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.94%. The ex-dividend date is Friday, June 28th. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Insider Activity at Stryker

In other news, CAO William E. Berry, Jr. sold 7,690 shares of the company’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total value of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Evercore ISI upped their price target on Stryker from $340.00 to $370.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. BTIG Research increased their price objective on shares of Stryker from $366.00 to $369.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Roth Mkm upped their target price on shares of Stryker from $348.00 to $405.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. Barclays raised their price target on shares of Stryker from $372.00 to $376.00 and gave the stock an “overweight” rating in a research note on Thursday, May 2nd. Finally, Piper Sandler boosted their price target on Stryker from $375.00 to $380.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $370.58.

Check Out Our Latest Stock Report on SYK

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Further Reading

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.